Different imaging techniques' diagnostic efficacy for Crohn's disease activity and external validation and comparison of MDCTAs, SES-CD and IBUSSAS

被引:0
作者
Long, Xingyun [1 ]
Peng, Chunyan [2 ]
Zhang, Xiaoqi [2 ]
Kong, Wentao [1 ]
Gong, Li [1 ]
机构
[1] Nanjing Med Univ, Nanjing Drum Tower Hosp, Drum Tower Clin Med Coll, Dept Ultrasonog, Nanjing 21009, Peoples R China
[2] Nanjing Drum Tower Hosp, Dept Gastroenterol, Nanjing 21009, Peoples R China
关键词
Crohn's Disease; Ultrasonography; Diagnostic imaging; Computed tomography; Endoscopy; INFLAMMATORY-BOWEL-DISEASE; COMPUTED-TOMOGRAPHY; ENTEROGRAPHY; MANAGEMENT;
D O I
10.1186/s12876-024-03376-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Crohn's disease (CD) is a chronic inflammatory disease of the digestive tract with unknown etiology. It follows a relapse-remission pattern, making disease activity assessment crucial for treatment. Our study aims to evaluate the diagnostic accuracy of various imaging modalities and to validate and compare the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS), the multidetector computed tomography enterography score (MDCTEs), and the simplified endoscopic activity score for Crohn's disease (SES-CD). Methods We assessed diagnostic performance using the CD Activity Index (CDAI). We first categorized patients into remission and active groups. For those in the active stage, we further categorized them into mild/moderate and severe activity groups. We used Spearman rank correlation to evaluate the relationships among IBUS-SAS, bowel wall thickness (BWT), Color Doppler imaging signal (CDS), inflammatory fat (i-fat), bowel wall stratification (BWS), and clinical inflammatory indicators. Results A total of 103 CD patients were evaluated. The IBUS-SAS cut-off for remission and activity was 23.8, with an AUC of 0.923, sensitivity of 91.4%, and specificity of 84.8%. The SES-CD had an AUC of 0.801, sensitivity of 62.9%, and specificity of 84.4% at a cut-off of 4.5. The MDCTEs showed an AUC of 0.855, sensitivity of 77.1%, and specificity of 75.8% for a cut-off of 6.5. The Delong test revealed significant differences in diagnostic efficacy when comparing IBUS-SAS to SES-CD and IBUS-SAS to MDCTEs. In the group of mild or moderate-to-severe active, the IBUS-SAS had an AUC of 0.925, sensitivity of 83.7%, and specificity of 88.9% at a cut-off of 40. The SES-CD exhibited an AUC of 0.850, sensitivity of 90.7%, and specificity of 70.4% at a cut-off of 8.5. MDCTEs showed an AUC of 0.909, sensitivity of 83.7%, and specificity of 85.2% at a cut-off of 8.5. During Delong test, the IBUS-SAS, MDCTEs, and SES-CD showed no significant differences in assessing moderate-to-severe activity. Both IBUS-SAS and ultrasound parameters correlated with certain serum indicators (p < 0.05), although only weakly to moderately (all r < 0.5). Conclusion The IBUS-SAS, MDCTEs and SES-CD can evaluate disease remission/active and mild/moderate-to-severe active in CD, and IBUS-SAS offers the potential to precisely define CD activity.
引用
收藏
页数:10
相关论文
共 32 条
  • [1] The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
    Alatab, Sudabeh
    Sepanlou, Sadaf G.
    Ikuta, Kevin
    Vahedi, Homayoon
    Bisignano, Catherine
    Safiri, Saeid
    Sadeghi, Anahita
    Nixon, Molly R.
    Abdoli, Amir
    Abolhassani, Hassan
    Alipour, Vahid
    Almadi, Majid A. H.
    Almasi-Hashiani, Amir
    Anushiravani, Amir
    Arabloo, Jalal
    Atique, Suleman
    Awasthi, Ashish
    Badawi, Alaa
    Baig, Atif A. A.
    Bhala, Neeraj
    Bijani, Ali
    Biondi, Antonio
    Borzi, Antonio M.
    Burke, Kristin E.
    Carvalho, Felix
    Daryani, Ahmad
    Dubey, Manisha
    Eftekhari, Aziz
    Fernandes, Eduarda
    Fernandes, Joao C.
    Fischer, Florian
    Haj-Mirzaian, Arvin
    Haj-Mirzaian, Arya
    Hasanzadeh, Amir
    Hashemian, Maryam
    Hay, Simon, I
    Hoang, Chi L.
    Househ, Mowafa
    Ilesanmi, Olayinka S.
    Balalami, Nader Jafari
    James, Spencer L.
    Kengne, Andre P.
    Malekzadeh, Masoud M.
    Merat, Shahin
    Meretoja, Tuomo J.
    Mestrovic, Tomislav
    Mirrakhimov, Erkin M.
    Mirzaei, Hamed
    Mohammad, Karzan A.
    Mokdad, Ali H.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (01): : 17 - 30
  • [2] Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease
    Bruining, David H.
    Zimmermann, Ellen M.
    Loftus, Edward V., Jr.
    Sandborn, William J.
    Sauer, Cary G.
    Strong, Scott A.
    Al-Hawary, Mahmoud
    Anupindi, Sudha
    Baker, Mark E.
    Darge, Kassa
    Dillman, Jonathan
    Einstein, David
    Fidler, Jeff L.
    Fletcher, Joel G.
    Gee, Michael S.
    Grand, David
    Guglielmo, Falvius
    Hara, Amy K.
    Jaffe, Tracy A.
    Maglinte, Dean
    Megibow, Alec
    Park, Seong Ho
    Platt, Joel
    Podberesky, Daniel
    Rimola, Jordi
    Sahani, Dushyant V.
    Soto, Jorge
    Taylor, Stuart A.
    [J]. GASTROENTEROLOGY, 2018, 154 (04) : 1172 - 1194
  • [3] Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application
    Bryant, Robert Venning
    Friedman, Antony B.
    Wright, Emily Kate
    Taylor, Kirstin M.
    Begun, Jakob
    Maconi, Giovanni
    Maaser, Christian
    Novak, Kerri L.
    Kucharzik, Torsten
    Atkinson, Nathan S. S.
    Asthana, Anil
    Gibson, Peter R.
    [J]. GUT, 2018, 67 (05) : 973 - 985
  • [4] Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
    Colombel, Jean-Frederic
    Panaccione, Remo
    Bossuyt, Peter
    Lukas, Milan
    Baert, Filip
    Vanasek, Tomas
    Danalioglu, Ahmet
    Novacek, Gottfried
    Armuzzi, Alessandro
    Hebuterne, Xavier
    Travis, Simon
    Danese, Silvio
    Reinisch, Walter
    Sandborn, William J.
    Rutgeerts, Paul
    Hommes, Daniel
    Schreiber, Stefan
    Neimark, Ezequiel
    Huang, Bidan
    Zhou, Qian
    Mendez, Paloma
    Petersson, Joel
    Wallace, Kori
    Robinson, Anne M.
    Thakkar, Roopal B.
    D'Haens, Geert
    [J]. LANCET, 2017, 390 (10114) : 2779 - 2789
  • [5] Management of Crohn Disease A Review
    Cushing, Kelly
    Higgins, Peter D. R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (01): : 69 - 80
  • [6] Catching the Therapeutic Window of Opportunity in Early Crohn's Disease
    Danese, Silvio
    Fiorino, Gionata
    Fernandes, Carlos
    Peyrin-Biroulet, Laureal
    [J]. CURRENT DRUG TARGETS, 2014, 15 (11) : 1056 - 1063
  • [7] Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
    Daperno, M
    D'Haens, G
    Van Assche, G
    Baert, F
    Bulois, P
    Maunoury, V
    Sostegni, R
    Rocca, R
    Pera, A
    Gevers, A
    Mary, JY
    Colombel, JF
    Rutgeerts, P
    [J]. GASTROINTESTINAL ENDOSCOPY, 2004, 60 (04) : 505 - 512
  • [8] Dragoni G, 2023, J Crohns Colitis
  • [9] Prospective Comparison of Computed Tomography Enterography and Magnetic Resonance Enterography for Assessment of Disease Activity and Complications in Ileocolonic Crohn's Disease
    Fiorino, G.
    Bonifacio, C.
    Peyrin-Biroulet, L.
    Minuti, F.
    Repici, A.
    Spinelli, A.
    Fries, W.
    Balzarini, L.
    Montorsi, M.
    Malesci, A.
    Danese, S.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 (05) : 1073 - 1080
  • [10] Use of the Crohn's disease activity index in clinical trials of biological agents
    Freeman, Hugh James
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (26) : 4127 - 4130